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1.1  Background 
 
The Nuclear Factor (NF) –κB was first discovered in 1986 via its 
interaction with an 11-base pair sequence (GGGGACTTTCC) in the 
immunoglobulin light-chain enhancer in B cells (κB). Because it was 
constitutively present only in B cells in an appropriate stage for light chain 
expression, NF-κB appeared to be a tissue-restricted transcription factor. 
However, it was shortly found in a masked cytoplasmatic form in all 
mammalian cell types(Sen and Baltimore 1986).  
Currently, the NF-κB family proteins has been described and implicated in 
the inducible expression of a wide array of genes encoding proteins essential 
for innate and adaptive immunity, inflammation and cell survival (Gilmore 
2006). Consistent with this role, mis-regulation of NF-κB activity has been 
related to cancer, inflammatory and autoimmune diseases, viral infection 
and improper immune development. In addition, several human genetic 
diseases, affecting components of the NF-κB signaling pathway, have been 
recently described.  
The ample role of NF-κB signaling in normal and disease physiology, is 
both its lure and its flaw as a therapeutic target. 
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1.2  The NF-κB family members 
 
The five NF-κB family members share structural homology with the 
retroviral oncoprotein v-Rel and Drosophila dorsal gene products resulting 
in their classification as NF-κB/Rel proteins (Gilmore 1999). All the 
members contain an N-terminus domain of approximately 300 amino acids 
called the Rel-homology domain (RHD), which mediates DNA binding, 
dimerization and nuclear localization. Generally, two subfamilies are 
distinguished: NF-κB and the Rel proteins. The NF-κB subfamily members 
named p50 and p52, which are the N-terminus fragments of the longer 
precursor NF-κB1/p105 and NF-κB2/p100 respectively, and the Rel 
subfamily members named RelA (p65), RelB and c-Rel, containing an 
unrelated C-terminus transcriptional activation domain, quite variable across 
species, even for a single Rel family member (Figure 1). 
These proteins can homo- or heterodimerize to form either transcriptionally 
active (e.g., p50-p65) or repressive (e.g., p50-p50) dimers. Targeted 
disruption of all NF-κB genes has been accomplished in mice, revealing a 
certain degree of redundancy among some of the family members. Mice 
lacking RelB develop normally to adulthood but display lack of lymph 
nodes and multi-focal defects in immune responses (Burkly, Hession et al. 
1995; Weih, Carrasco et al. 1995). Mice lacking other NF-κB proteins, 
including c-Rel and p52, have immune defects also (Kontgen, Grumont et 
al. 1995). However, there are also clear examples for exclusive roles of 
single Rel proteins. For instance, RelA-deficient mice die during 
embryogenesis because of massive, TNFα-induced apoptosis in the liver, 
demonstrating a vital, anti-apoptotic and unshared role of RelA (Hoffmann, 
Leung et al. 2003). 
 
1.3  Signaling to NF-κB 
 
Activation of the NF-κB signaling pathway is regulated at several 
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levels. Even so, the family of proteins called Inibitor of -κB (IκBs) play a 
primary role in regulation of NF-κB activity.  
In the resting cells, NF-κB dimers are retained as latent proteins through 
their association with IκBs. Following cell stimulation with any of a 
multitude of agonists, IκB proteins are rapidly phosphorylated by the IκB 
kinase complex (IKK), K-48 ubiquitinated and then degraded by the 26S 
proteasome (classically p65/p50-bound IκBα). The freed NF-κB dimers can 
move into the nucleus, where they bind to specific sequences in the 
promoter or enhancer regions of target genes (Figure 2) (Bonizzi and Karin 
2004). Transcription of target genes is further regulated through 
posttranslational modifications of NF-κB dimers that affect its ability to 
interact with transcriptional coactivators. NF-κB-dependent transcription of 
IκB proteins, as well as additional mechanisms targeting DNA-bound NF-
κB dimers, terminate the response (Hayden and Ghosh 2008).  
In mammalian, three main members compose the IκB family of 
proteins: IκBα, IκBβ, IκBε. These proteins, characterized by the presence of 
multiple copies of ankyrin repeats (ANK), bound to NF-κB dimers masking 
the Nuclear Localization Signal (NLS) present in its RHD, thereby 
preventing nuclear entry and DNA binding (Gilmore 2006). All of these IκB 
proteins contain a conserved motif, near their N-termini, consisting of two 
serine residues, phosphorylated by IKK, and one or two lysine residues 
target of K-48-ubiquitination (Figure 1). 
The precursor NF-κB1/p105 and NF-κB2/p100 contain the ankyrin repeats 
also, functioning as IκB-like proteins maintaining their NF-κB-subunit 
dimeric partners in the cytoplasm (Karin and Ben-Neriah 2000).  
Furthermore, there are two “atypical” IκB proteins called Bcl-3 (BCL3) and 
IκBζ (NFKBZ), which have inducible expression and appear to regulate NF-
κB by a distinct mechanism. It has been demonstrated that they interact with 
p50 and p52 containing complexes bound to the promoter and they can 
either inhibit or promote transcriptional responses (Hayden and Ghosh 
2008). 
A pivotal regulator of inducible NF-κB signaling pathways is the IκB kinase 
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(IKK) complex. This complex consists of two kinases, IKK1 (or IKK-α) 
and IKK2 (or IKK-β), and a regulatory subunit named NF-κB essential 
modulator, NEMO (or IKKγ).  
Genetic analysis of the IKK complex has identified two separate 
pathways named the canonical and non-canonical mechanisms that are 
dependent on either NEMO and IKK2 or IKK1 alone.  
The non-canonical or “alternative” pathway operates mainly in B-cells in 
response to stimulation of a subset of the TNF-receptor superfamily, 
including receptors for BAFF, lymphotoxin-β (LTβ) and CD40 ligand. 
Stimulation of these receptors results in the activation of the IKKα subunit 
that in turn phosphorylates the p100/p100 dimers, causing its inducible 
processing to the transcriptionally active form p52 (Xiao, Fong et al. 2004). 
The principal NF-κB signaling pathway is the “canonical”, that occurs upon 
the stimulation of many receptors such as the Toll-like Receptors (TLRs) in 
the innate immune response, T cell Receptor (TCR) in the adaptative 
immunity, TNF Receptor (TNFR) or Interleukin-1 Receptors (IL-1R) in 
inflammation or in response to a variety of endogenous ligands (such as 
viral DNAs or RNAs). Following ligand/receptor association, a complex 
cascade of events is activated. A wide range of adaptor and scaffolding 
proteins are recruited to the receptor preceding the activation of a number of 
intermediate kinases. Each signaling cascade employed unique or 
overlapping combinations of these upstream intermediates to transmit 
information from the cell surface to the NF-κB-IκB complexes. 
Beside the variety of stimuli and molecules involved in the activation of 
“canonical” NF-κB activation, the common feature is the activation of the 
IKK complex (Figure 2). Accordingly, it represents the core regulatory step 
in the NF-κB response (Hayden and Ghosh 2008).  
 
1.4  The Iκb Kinase complex: the master regulator of 
NF-κB signaling 
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The pivotal IKK complex is the kinase complex responsible of IκB 
protein phosphorylation. It is composed of two related catalytic subunits 
IKK1 (or IKK-α) and IKK2 (or IKK-β), of regulatory subunit NEMO (or 
IKK-γ) and  accessory proteins such as Hsp90, cdc37 and ELKS, whose 
functions are either not NF-κB specific whether fully characterized. By 
contrast to these IKK-associated proteins, the role of the core IKK subunits 
has been well established by a variety of genetic experiments, most 
importantly gene ablations in mice. Although both IKK1 and IKK2 are 
necessary for survival of mouse embryos, their respective roles in 
embryonic development and survival are quite different (Hayden and Ghosh 
2008). IKK1 has a unique function in skin and skeletal development, as well 
as in B cell maturation, and its absence cannot be compensated for by IKK2 
(Hu, Baud et al. 2001). In contrast, IKK2 appears to play an indispensable 
role in inducible NF-κB activation in response to pro-inflammatory and pro-
apoptotic stimuli. In absence of IKK2 embryonic lethality, liver 
degeneration is observed, similar to p65 knockout mice (Li, Chu et al. 
1999). Severe liver degeneration and early lethality were also observed in 
embryos that were deficient in the NEMO subunit (Schmidt-Supprian, 
Bloch et al. 2000).  
The two kinases share important structural identity and both contain 
an N-ter catalytic domain, a central leucine zipper motif through which they 
heterodimerize, a helix-loop-helix domain and a NEMO-Binding Domain at 
the C-terminus region (Figure 3). These proteins seem to have redundant 
functions, even if it has been shown that IKK2 is both necessary and 
sufficient for the phosphorylation of IκBα on Ser32 and Ser36, and IκBβ on 
Ser19 and Ser23.  
NEMO does not have enzymatic activity, although, genetic studies 
have clearly demonstrated that NEMO is necessary for a proper NF-κB 
activation in response to most stimuli. NEMO is a 48kDa regulatory subunit 
that contains two coiled-coil motifs, denoted as CC1 and CC2, a Leucine 
Zipper and a Zinc Finger domain in the C-terminus region and a newly 
characterized Ubiquitin Binding Domain (UBD) that confers to NEMO the 
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ability to bind to polyubiquitinated proteins (Figure 3). CC1 domain 
overlaps with the IKK-binding domain (44-111aa), whereas the CC2-LZ 
and ZF domain play a regulatory role.  
It has been proposed that multiple combinations of the IKK complex 
subunits exist including homodimers of IKK1 or IKK2 either associated or 
distinct from NEMO. The apparent molecular mass of the resting IKK 
complex has been shown to be in the 700-900 kDa range, suggesting that it 
may contain multiple copies of its constituents and that its size varies in a 
stimulus-dependent manner. However, biochemical evidence indicates that 
the majority of cellular IKK complexes contain a core of IKK1-IKK2-
NEMO in the ratio of 1:1:2. NEMO exists as a partially folded dimer 
associated with the two kinases. Probably, the complex is maintained trough 
multiple interactions with chaperone proteins like Hsp90, Hsp70 and 
CDC37 (Hayden and Ghosh 2008; Rushe, Silvian et al. 2008). 
Current evidence show that the activation of the IKK complex is 
mediated by its recruitment to receptor-containing complex signalosomes, 
where, the final event for IKK activation seems to be its phosphorylation at 
specific Serines in the T loop of the catalytic domain of each kinases (Figure 
3). Substitution of these serine residues with alanine makes both kinases 
catalytically inactive, whereas phosphomimic mutations in which the 
residues are substituted with glutamic acid generate constitutively active 
IKKs (Hacker and Karin 2006). The mechanism through which this 
phosphorylation occurs remains unclear, however, two mechanisms have 
been proposed. The first possibility is that the IKKs phosphorylates each 
other by transautophosphorylation. The second plausible mechanism could 
be the existence of unconnected kinases (IKK-Ks) that target the residues 
within the T loop. It is also possible that both mechanisms can occur 
independently or together in a manner that is dependent upon the nature of 
the specific upstream signaling pathway.  
In contrast to this latter case, the critical role of NEMO for IKK-mediated 
activation has been definitively established.  
NEMO is the point of convergence of most stimuli activating NF-
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κB, its interaction with signaling intermediates is essential for the correct 
IKK complex recruitment and activation. NEMO lacking cells fail to 
activate NF-κB in response to proinflammatory cytokines such as Tumor 
Necrosis Factor (TNF)-alfa, Interleukin (IL)-1 and bacterial 
lipopolysaccaride (LPS). In addition, NEMO mutations have been 
associated to human genetic pathologies (discussed below).  
NEMO interacts as a dimer together with IKK1 and IKK2, it can also 
oligomerize via a minimal oligomerizazion domain (MOD), constituted by 
the second CC region and the LZ domain (also colled CoZi domain) (Agou, 
Courtois et al. 2004). It has been proposed that a change in the oligomeric 
state of NEMO may represent a recurrent mechanism of IKK activation, as 
mutations within the MOD can block IKK activation (Inohara, Koseki et al. 
2000; Poyet, Srinivasula et al. 2000). Nevertheless, its oligomeric state still 
remains matter of controversy for the reason that a range of oligomeric 
states have been reported. Recent evidences demonstrated the existence of 
stimuli-induced posttranslational modifications of NEMO (discussed below) 
that could induce conformational change without variation in the 
stechiometry of the complex composition.  
Indeed, numerous proteins, producing either NF-κB activation or inhibition, 
have been shown to interact with NEMO (Table 1) indicating that NEMO 
might act as a carrier responsible for bringing IKK-complex in close 
proximity to activators such as TGFbeta-activating kinase (TAK) to 
promote its phosphorylation and activation (Sebban, Yamaoka et al. 2006). 
NEMO also appears to control the downregulation phase of transient IKK 
activity. It has been demonstrated that NEMO serves as the docking 
platform for several negative regulatory proteins including the 
deubiquitinases A20 and CYLD (Kovalenko, Chable-Bessia et al. 2003)and 
the protein phosphatases PP2A and PP2C that may inhibit IKK activity by 
removing phosphates from the T loop serines (Fu, Kuo et al. 2003). 
Several other proteins are also supposed to interact with NEMO but in most 
cases the functional relevance of this interaction is not precisely understood 
(Table 1). 
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Moreover, it has been recently shown that specific phosphorilation on Ser 
68 of NEMO leads to downregulation of IKKactivity, supporting a model in 
which IKK C-terminus autophosphorylation and phosophorylation of 
NEMO within the IKK-binding region leads to conformational changes that 
possibly recruit negative regulatory proteins to inhibit IKK function 
(Palkowitsch, Leidner et al. 2008). 
 
1.5  Ubiquitin-Mediated Activation of IKKcomplex in 
the NF-κB Pathway 
 
1.5.1 The ubiquitination code  
 
Ubiquitination has became a predominant topic in many fields of 
biology research, owing its role in regulation of various cellular processes.  
Ubiquitin (Ub) is a 76 aa highly conserved globular protein that is 
covalently attached to lysine (Lys) residues of target proteins. This covalent 
modification, know as ubiquitination, is carried out by a sequence of 
enzymatic reactions involving three main components. First, an ubiquitin 
activating enzyme (E1) uses ATP to catalyses the formation of a thioester 
bond between the C-terminus of ubiquitin and its active cysteine. Then, the 
latter ubiquitin is passed to a conjugating enzyme (E2 or UBC) forming an 
E2-ubiquitin thioester. Finally, ubiquitin is covalently attached to substrates 
through the formation of an isopeptide bonds between the ubiquitin C-
terminus and the ε-amino group of lysines on the target protein. The 
enzymes responsible for this last step, the ubiquitin ligases (E3), are the 
ones which provide target specificity by directly interacting with its 
substrates (Pickart 2004) (Figure 4A).  
Depending on the E2/E3 machinery, mono- or polyubiquitination of 
proteins can be achieved. These two modifications are associated to 
different functional outcomes (Figure 4B).  
Monoubiquitination is the attachment of a single ubiquitin to a protein; 
multiubiquitination occurs when several Lys residues of the target protein 
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are tagged with single Ub molecules. Monoubiquitination is an important 
modification and primarily serves to regulate the internalization of cell-
surface proteins, intracellular protein sorting, and other cellular activities. 
Monoubiquitination of several residues on one substrate results in multiple 
monoubiquitination, which may promote subcellular relocalization or target 
substrates to the endosome- (as opposed to proteasome-) mediated 
degradation system (Mukhopadhyay and Riezman 2007). 
Polyubiquitination consists in the addition of a polyubiquitin chain to 
the target protein. It is important to reiterate that the amino terminus of the 
group of lisine residues on ubiquitin may also serve as substrates for 
ubiquitination thus, the chain comprises several ubiquitins in which the C-
terminus glycine residue of each ubiquitin is linked to a specific internal Lys 
of the previously attached ubiquitin. Because there are seven internal lysines 
in ubiquitin (K6, K11, K27, K29, K33, K48 and K63) at least seven 
different linkages between ubiquitins are possible (Ikeda and Dikic 2008) 
(Figure 4B).  
The different linkages in polyubiquitin chains have different effects on the 
substrate and their role have begun to be elucidated in recent years. K48-
linked polyubiquitinated chains are originally identified to deliver a “kiss of 
death” to the target protein, resulting in recognition and degradation by the 
26S proteasome (Thrower, Hoffman et al. 2000). In contrast, when K63-
linked polyubiquitinated chains are added to proteins no efficient 
degradation is observed but the target protein function is modified by 
various mechanisms (Geetha, Jiang et al. 2005). For instance, ubiquitination 
can provide a platform as three-dimensional signals for recruiting partners, 
an event which requires ubiquitin-binding (UB) proteins recognizing the 
specific patterns of ubiquitination on substrate proteins and direct the 
substrates to the appropriate fate (Figure 4B).  
At present, close to 20 diverse types of UB Domains (UBDs), which 
are relatively different in terms of size, structure and function, have been 
identified (Hicke, Schubert et al. 2005). In this way, the distinct ubiquitin 
arrangements on substrates can promote specific outcomes. 
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Similar to phosphorylation, ubiquitination is a reversible process that is 
regulated at different levels. To this regard, the De-UBiquitination enzymes, 
(DUBs) that reverse the ubiquitin reaction, have an important role.  
The ubiquitination event occurs in response to extra cellular stimuli and 
often the substrates are not constitutively recognized. Therefore, the activity 
of the ubiquitin system needs to be quickly and tightly regulated in order to 
increase specificity. This could be achieved by promoting or inhibiting 
substrate recognition. 
Regulation can also occur through post-translational modification of a 
component of the ubiquitin conjugating machinery. Generally, the E3 
ligases are the main component of the machinery subject to regulation. The 
two distinct E3 ligase family, the HECT-type and RING-type, both appear 
to be regulated by related modifications, e.g. ubiquitination and 
phosphorylation, that can either inhibit or promote E3 activity (Brown, 
Hostager et al. 2002; Yang, Zhou et al. 2006). 
 
1.5.2 Ubiquitin-Mediated Activation of IKK complex  
 
The multiplicity of ubiquitin role in protein kinase activation has 
been discovered in the course of studying the NF-κB signaling pathway.  
It was originally shown that the kinase activity could be started by 
polyubiquitination processes, which are different from the ones leading to 
protein degradation observed in the case of IκBα (Chen, Parent et al. 1996). 
In the NF-κB signaling, K63-linked ubiquitination has been observed to 
modify several distinct molecules participating in IKK activation. In 
addition, some components of signaling pathways leading to IKK/NF-κB 
activation exhibit ubiquitin-binding properties (Table 2). This provides a 
complex framework of protein/protein interactions that is fine regulated by 
enzymes with deubiquitinating activity such as A20 and CYLD. In several 
instances, this framework has been elucidated to some extent. 
The role of ubiquitin in IKK activation was first discovered in the course of 
studying the IL-1 signaling pathway. Upon stimulation of the IL-1 receptor 
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several proteins including the adaptor protein MyD88, the kinases IRAK1 
and IRAK4, and TNF-R Associated Factor (TRAF) 6 are recruited to the 
receptor complex (Figure 5).  
TRAF6 is an E3 ubiquitin ligase, containing a highly conserved N-ter RING 
domain, that catalyses K63-linked polyubiquitin chains (Deng, Wang et al. 
2000). This K63 polyubiquitination seem to be an essential event leading 
the TAK kinase complex activation, probably by autophosphorylation, 
which in turn phosphorylates IKK2, resulting in IKK activation (Wang, 
Deng et al. 2001). The polyubiquitin chains, some of which are conjugated 
to TRAF6 itself, seem to function as scaffold to recruit TAK and IKK 
complex through binding the regulatory subunits, TAB2 and NEMO, 
respectively. The TAK1 kinase complex consists of TAK1 and its 
associated proteins TAB1 and TAB2 or TAB3 (Ishitani, Takaesu et al. 
2003). TAB2 and TAB3 are homologous proteins that contain a C-terminus 
conserved UBD (NZF-type) conferring on TAB2 and TAB3 the ability to 
bind preferentially to K63 polyubiquitin chains. Mutations within the NZF 
domain that impair the ability of TAB2 and TAB3 to bind to polyubiquitin 
chains also abrogate their ability to activate TAK1 and IKK (Skaug, Jiang et 
al. 2009) (Table 2).  
Likewise, NEMO represents an interesting case of K63 poliubiquitin 
chains recognition. Pull-down experiments have demonstrated that the 
region encompassing the second coiled-coil and the leucine zipper motifs 
(called NUB, NEMO Ubiquitin Binding domain, Figure 3) is unrelated to 
any other previously identified UBD, corresponds to an evolutionnary 
conserved sequence which is also present in other proteins ABIN1-3 and 
Optineurin (Wagner, Carpentier et al. 2008).  One physiological substrate of 
NEMO is receptor-interacting protein, RIP, which is indeed K63-
ubiquitinated within minutes of TNFalfa stimulation. Mutation of the key 
Ub-acceptor lysines of RIP (K377) abrogates NEMO binding and 
subsequent IKK activation (Ea, Deng et al. 2006; Li, Kobayashi et al. 2006). 
Although NEMO and RIP can directly interact in vitro (Zhang, Kovalenko 
et al. 2000), the polyubiquitination of RIP upon TNF stimulation seems to 
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be the event determining their interaction in vivo. Recent studies, using an 
antibody specific for K63 polyubiquitin chains, have confirmed that RIP1 is 
conjugated by the K63 polyubiquitin chains following TNFalfa stimulation 
(Newton, Matsumoto et al. 2008). RIP1 is also K48-ubiquitinated and 
targeted for degradation by an ubiquitin complex containing the 
deubiquitination enzyme A20. It has been proposed that NEMO protects 
RIP1 from the proteasomal degradation by preventing the conversion of 
K63-linked to K48-linked polyubiquitination promoted by the A20 protein.  
Also in this case, the function of the polyubiquitin chain on RIP1 appears to 
be the recruitment of the TAK1 and the IKK complexes to the TNFR. This 
mechanism of recruitment to RIP1 may serve as a paradigm for the role of 
K63-linked ubiquitin in the NF-κB pathway providing an elegant and 
compelling model that can be expanded to other pathways, including those 
involving TLR that operates by similar ways and differs principally in the 
TRAFs paralogue used (Figure 5).  
Although these evidences highlight the importance of ubiquitin 
binding in kinase regulation, the mechanism by which binding to 
poliubiquitineted proteins leads to the activation of kinase complex remains 
to be elucidated. Structural studies about NEMO and TAB2 UBDs will 
provide important informations to propose a definitive model of activation.  
Interestingly, the importance of ubiquitination in the IKK activation is also 
underlined by the significant role of DUB enzymes, such as CYLD and 
A20, which disassemble K63 polyubiquitin chains to inhibit the signaling 
cascade. 
CYLD is the first DUB discovered to negatively regulate TRAFs induced 
IKK activation (Kovalenko, Chable-Bessia et al. 2003). Mutations in CYLD 
have been identified in patients with familial cylindromatosis in which 
affected individuals develop multiple benign tumors of the skin appendages. 
(Bignell, Warren et al. 2000). This combination of genetic and biochemical 
evidence strongly suggests that ubiquitin-mediated regulation of IKK 
activation has a critical role in human physiology and that its misregulation 
can have devastating consequences. 
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Adding another level of complexity to the mechanism(s) of IKK 
complex activation, it has been demonstrated that NEMO may also be a 
target for K63-linked poliubiquitination in a variety of signaling cascades. 
This event appears to have an impact on its function (Figure 5). TNF 
stimulation induces NEMO K63-linked poliubiquitination probably 
mediated by TRAF2 and cIAPs. Mutations in the NEMO ZF domain also 
impair the ubiquitination event (Tang, Wang et al. 2003). 
Engagement of the TCR- and BCR also induces NEMO ubiquitination, in 
this case MALT-1 is the E3 ligase responsible for both its mode of action 
and its functional relationship to TRAF-2 and TRAF-6, which seem also to 
participate in TCR and BCR signaling (Sun, Deng et al. 2004). 
 
1.5.3 TRAFs: The key intermediates in most NF-κB pathways  
 
TRAFs [tumor necrosis factor (TNF) receptor (TNFR)-associated 
factors] are a family of  seven proteins that have important roles in signal 
transduction of TNFR and IL-1 receptor (IL-1R) toll-like receptor (TLR) 
superfamilies and B cell receptor (BCR). A wide range of biological 
functions, such as inflammatory response, immunity, and bone metabolism, 
rely on the proper functions of TRAF proteins to activate IKK complex and 
MAP kinases, leading to activation of NF-κB and AP-1 respectively. 
All TRAF proteins, except TRAF7, contain at C-terminus TRAF domain 
which contains a TRAF-N domain predicted form a coiled coil and an 
highly conserved TRAF-C domain, which mediates homo- and hetero- 
dimerization, as well as their association with members of the TNFR and 
IL-1R–TLR receptor families (Park, Burkitt et al. 1999). Two additional 
functional domains at the N terminus, a variable number of zinc fingers 
domain and the RING domain, are shared by TRAF2–TRAF7. 
The RING domain is important for downstream signaling by TRAF 
proteins. Unlike most E3s containing the RING domain, the primary 
function of TRAF2 and TRAF6 is not to target protein for degradation but 
to activate downstream IKK cascades (Deng, Wang et al. 2000). These 
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TRAF proteins function in conjunction with the Ub-conjugating enzyme 
(E2) to catalyze the formation of K63-linked polyubiquitin chain. They do 
not seem to have catalytic activity but provide a connection between E2s 
and the substrate. Notably, TRAF2, 3 and 5 seem to contribute only in TNF 
receptor signal transduction while, TRAF6 has been implicated in the 
trasduction of many receptor signals (Pineda, Ea et al. 2007), including Toll 
and IL-1 receptor. TRAF2 and TRAF6 overexpression is sufficient to 
induce activation of the canonical NF-κB pathway. Biochemical studies 
demonstrated that TRAF6 (and TRAF2 also) is subject to self-
polyubiquitination (K63), revealing a critical role of this kind of 
posttranslational modification (Lamothe, Besse et al. 2007; Lamothe, 
Campos et al. 2008). However, the exact mechanism by which these 
proteins act is still unclear. 
 
1.6  Inherited human genetic diseases caused by 
mutation in the NEMO gene 
 
The human gene encoding NEMO, the Inhibitor of Kappa light 
polypeptide gene enhancer in B-cells, Kinase Gamma (IΚBKG; 
NM_003639.3), is a 23 Kilo base (Kb) gene structured in 9 exons and 4 
alternative non coding first exons located on the X chromosome (Xq28) 
(Smahi, Courtois et al. 2000). 
NEMO mutations have been associated with several distinct X-linked 
genetic diseases. 
 
1.6.1 The Incontinentia Pigmenti  
 
Incontinentia Pigmenti (IP; OMIM#308300) is the first genetic 
disease associated to NF-κB alteration. IP is a severe X-linked dominant 
genodermatosis which is lethal in males (Landy and Donnai 1993) and in 
females has a highly variable and often severe clinical presentation always 
associated with skin defects characterised by four distinct dermatological 
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stages. IP female patients can also suffer from severe ophthalmological, 
odontological or neurological defects (Hadj-Rabia, Froidevaux et al. 2003). 
A very striking feature of the IP pathology is the extensive X inactivation 
skewing that is observed in the peripheral blood cells of heterozygous IP 
females (Fusco, Bardaro et al. 2004). 
The gene responsible for IP, NEMO, is mutated in 73% of IP patients 
screened. It encodes for the regulatory subunit of the Inhibitor of KappaB 
Kinase (IKK) complex (NEMO) required for a proper NF-κB activation 
(Smahi, Courtois et al. 2000). IP is the first described inherited disease 
associated with mutations affecting one of the core components of the NF-
κB signaling pathway.  
In IP patients, a recurrent deletion occurs. This rearrangement leads 
to an excision of the region between two MEdium Reiterated 67B 
(MER67B) repeated sequences, producing an aberrant protein in which 26 
novel amino acids are attached to the 133 residues encoded by exons 2 and 
3. As a result, cells from rearranged IP patients do not activate NF-κB in 
response to cytokines and are highly sensitive to TNF-α-induced apoptosis 
(Aradhya, Woffendin et al. 2001).  
Besides the exon 4_10 rearrangement, other NEMO mutations have been 
identified (small duplications, substitutions or deletions) scattered along the 
gene. Although many of them such as nonsense or frameshift mutations 
result in a large truncation or extension of the NEMO protein, several 
missense mutations have also been reported. The observation that IP-
causing mutations affect all exons of the NEMO gene is consistent with the 
importance of the entire amino acid sequence for its function.  
The phenotype of IP patients is difficult to interpret, owing to the X-
mosaicism. Schmidt-Supprian and colleagues have engineered Nemo 
knockout mice (KO) (Schmidt-Supprian, Bloch et al. 2000). Male mice die 
very early during embryogenesis from massive liver apoptosis triggered by 
TNF-α. In contrast to males, KO female mice develop normally but, soon 
after birth, exhibit patchy skin lesions with massive granulocyte infiltration. 
Similar to IP patients the lesions are associated with hyperproliferation and 
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increased apoptosis of keratinocytes. In addition, the extensive X-
inactivation skewing in blood leukocytes is also observed in Nemo KO 
mice. 
The data collected from the mouse models could provide a putative 
explanation for the IP phenotype. In most cells, such as circulating blood 
cells or hepatocytes, X-inactivation appears severely skewed, because of 
selection against cells carrying the NEMO mutated locus. Probably, at the 
skin level, elimination of mutated cells starts only after birth generating 
dermatosis observed in all IP patients. The initial signals triggering this 
event is still unknown, probably certain kind of stress might induce necrosis 
of Nemo (-) keratinocytes. This would cause a local inflammation response 
and the secretion of cytokines, such as TNF-α. As a consequence, NEMO 
lacking cells would die as a result of TNF-α-induced apoptosis, caused by a 
complete abolition of the NF-κB signaling pathway (Sebban and Courtois 
2006) (Figure 6). 
 
1.6.2 EDA-ID  
 
Genetic studies have revealed that IP is allelic with an X-Recessive 
Immunodeficiency syndrome termed Anhydrotic Ectodermal Dysplasia with 
severe ImmunoDeficiency (EDA-ID, OMIM#300291), a very rare disease 
exclusively affecting males. It combines the severe sensitivity to infection 
with abnormal development of skin adnexa (hair follicles, sweat glands and 
teeth). This disease is due to NEMO hypomorphic mutations, often missense 
or small deletions/insertions, which mainly affect the Zinc Finger (ZF) 
domain of the protein. These mutations reduce but do not eliminate NF-κB 
activation explaining why affected male patients survive (Zonana, Elder et 
al. 2000; Doffinger, Smahi et al. 2001; Kenwrick, Woffendin et al. 2001)  
A quite remarkable difference in clinical signs has been observed between 
IP females and EDA-ID males. This diversity could be due to the different 
type and location of the mutations that cause the two diseases, but also to 
the mosaic expression of NEMO due to random X inactivation in 
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heterozygous females. Indeed, a rapid progressive selection against 
peripheral blood cells carrying the mutated X-chromosome can explain why 
IP patients do not suffer from immunodefiency while EDA-ID patients 
always present a severe sensitivity to infections (Courtois and Gilmore 
2006).
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NF-κB is an ubiquitous transcription factor involved in a variety of 
biological processes, such as inflammation, immunity, cell survival and 
development. In the resting cells NF-κB dimers are retained as latent protein 
through their association with IκB. In response to several stimuli, such as 
pro-inflammatory cytokines, NF-κB dimers became active translocating to 
the nucleus, where they bind to specific sequences in the promoter or 
enhancer regions of target genes. 
The NF-κB signaling pathways emanating from the TNFR receptors IL1R 
and TCR4 have been most studied. In NF-κB canonical activation, 
following ligand/receptor interaction, adaptor molecules and kinases are 
recruited to the receptor and all the signals converge on the pivotal IKK 
complex, which is composed by two related catalytic subunits, IKK1 and 
IKK2, and a regulatory subunit called NEMO. One of the main questions 
about the activation of NF-κB is how the IKK-complex is activated. To this 
regard, the central role of NEMO in mediating canonical NF-κB activation 
pathways has been largely demonstrated through biochemical and genetic 
studies but how NEMO can integrate the various signaling pathways 
regulating the activity of IKK complex is still unknown.  
The whole amino acid sequence of NEMO is required for a correct 
assembly and recruitment of the IKK complex to upstream signaling 
molecules. Supporting this view, numerous proteins producing either NF-
κB activation or inhibition have been shown to interact with NEMO and in 
turn, regulate the IKK activity. Furthermore, several lines of evidences have 
revealed the existence of many regulatory posttransational modifications of 
NEMO, e,g. K63-linked polyubiquitination, that occur in response to 
specific stimuli at specific sites and seem to be essential for its function 
(Sebban, Yamaoka et al. 2006). Despite their indispensability in several 
pathways, the precise mechanisms by which NEMO activity is regulated by 
posttranslational modification remain unclear.  
Given the critical role of NEMO, it is not a surprise that NEMO 
mutations are causative of human diseases. The first described is 
Incontinentia Pigmenti (IP), an X-linked dominant and male-lethal disease. 
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Heterozygous IP females can survive owing to X-inactivation mosaicism 
and present neonatal rush, and frequently malformations of eyes, teeth and 
central nervous system. The overall objective of my thesis is to contribute in 
ameliorate our understanding of the genetic and pathological aspects of 
NEMO-related diseases. In order to get insights into the molecular 
mechanisms that underline the alteration of NF-κB during pathology, we 
combined the characterization of human disease-associated mutations with 
the elucidation of the IKK activation process NEMO-dependent. To date, 
only few NEMO missense mutations have been characterized at functional 
level. Through the molecular characterization of missense mutations I will 
define the critical residues of NEMO required for proper protein/protein 
interaction and/or the specific residues that are target of regulatory 
modifications, e.g. K-63 polyubiquitination, essential for a correct signal 
transduction.  
Importantly, a better understanding of IP at the cellular and 
molecular levels could offer useful information to dissect the NF-κB 
regulation in order to propose new therapeutic options, not only for this 
specific pathology but also for more common pathologies resulting from 
NF-κB dysfunction. 
 
. 
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3.1   Case report 
 
Patient KB is a 12 year old female who developed cutaneous rash 
with vescicles on the trunk and the limbs (first stage of IP) at 1 month of 
age. Those vescicles then became hyperkeratotic warty lesions (second 
stage) at 3 months of age. In the third stage, pigmented spots appeared in 
linear and whorled pattern on the trunk and the limbs (at 1 year), while the 
fourth stage has not appeared at the time of the NEMO molecular analysis. 
Skin biopsies performed at the first stage confirmed marked dyskeratosis 
and eosinophilic infiltration consistent with IP.  
No alterations were observed in the hair, fingernails and eyes. In contrast, 
neurological alterations were present: microcephaly, brain atrophy, were 
diagnosed at birth and at the same time CT scan analysis showed severe 
cortico-subcortical atrophy, mostly in the left hemisphere. Neonatal seizures 
were observed at the time of IP diagnosis (1 month of age). Mental 
retardation and learning difficulties were diagnosed at 3 years.  
The patient is the second child in the family with 4 siblings. However, the 
other members of the family, parents and 3 siblings, were examined and 
nobody was IP affected. 
 
3.2  Reagents 
 
The following antibodies were used: anti-human NEMO (sc-8330 
Santa-Cruz), anti-mouse NEMO (#3329, a kind gift of N. Rice), anti-IKK-1 
(Imgenex), anti-IKK-2 (Imgenex), anti-RIP (Imgenex), anti-TRAF-6 (sc-
7221, Santa-Cruz), anti-RICK (sc-22763, Santa-Cruz) and anti-phospho-
JNK (Cell Signaling), TNF-α and IL-1β were from Roche and Peprotech, 
LPS and LPA were from Sigma.  
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3.3  Mutation dectection and X-inactivation analysis 
 
Mutation G967C of NEMO was identified and X-inactivation 
skewing was measured using protocols described previously for other 
NEMO mutations (Fusco, Bardaro et al. 2004). 
 
3.4  Plasmid construction 
 
The full-length human NEMO cDNA was inserted between the Hind 
III and Not I sites of the pcDNA3 vector. I generated plasmids carrying the 
point-mutations found in IP patients using the Quick-change site-directed 
mutagenesis kit (Stratagene). The sequence of all the mutated constructs 
was checked by automatic directed sequencing, using T7 and Sp6 primers. 
The same procedure was used to prepare all the point mutations in the full 
length version of mNEMO, previously inserted into a pcDNA3-HA 
expression vector. The truncated versions of mNEMO (dN241, dC385, 
dC343 and dC299) were generated by PCR and inserted into pcDNA3-HA. 
The pBabe-NEMO plasmid and its mutants were produced by PCR .  
 
3.5  Cell culture  
 
HEK293T, Mefs and LinX cells were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM, Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 100mg/ml 
streptomycin and 1% glutamine at 37°C in 5% CO2. 1,3E2 cells were 
grown in RPMI (GIBCO) containing 10% fetal bovine serum, 1%, 
antibiotics (100 U/ml penicillin, 100 mg/ml streptomycin) and 50 µM b-
mercaptoethanol at 37°C in 5% CO2. 
 
3.6  Transfections 
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1.3E2 cells were transfected using DEAE-Dextran, as previously 
described (26). Transfection of SVT-2C cells was performed similarly. 
Briefly, 5 X 106 cells were washed in TBS (25 mM Tris-HCl (pH 7.4), 137 
mM NaCl, 5 mM KCl, 0.6 mM Na2HPO4, 0.7 mM CaCl2, 0.5 mM 
MgCl2), resuspended in 250 µl of TBS, and NEMO expression plasmid 
(200 ng), Igk-Luc reporter plasmid (1 µg) and internal control eF1-LacZ 
(200 ng) were added. Cells were finally mixed with 250 µl of DEAE-
Dextran (1 mg/ml, diluted in TBS). After 45 min of incubation at room 
temperature, cells were diluted with 5 ml of TBS, centrifuged and 
resuspended in 5 ml of RPMI/10% FCS. Twenty-four hours later cells were 
recovered in 100 µl of Lysis Buffer (LB) (25 mM Tris-phosphate (pH 7. 8), 
8 mM MgCl2, 1 mM DTT, Triton X100, 25% glycerol) and luciferase 
activity was assessed using the Luciferase Assay system (Promega). 
Transfection of NEMO (-) MEFs was carried out by electroporation. 
Briefly, the cell equivalent of a confluent 10 cm2 dish was resuspended in 
300 µl of PBS and 100 µl were electroporated (500 µF, 160V, Gene Pulser 
X-cell Electroporation System, BioRad) after adding 1 µg of reporter 
plasmid, 200 ng of eF1-LacZ and 500 ng of NEMO expression vector. After 
electroporation, cells were resuspended in 9 ml of DMEM/10% FCS and 
used to fill 3 wells of a 6 well dish. The morning after, the medium was 
changed. In the evening, cells were serum starved by adding DMEM 
without FCS. After 16 h of starvation, cells were mock-, TNF- (10 ng/ml), 
IL-1- (10 ng/ml) or LPS- (15 µg/ml) stimulated. Four hours later, cells were 
lysed with LB and luciferase was measured as described above.  
Transfection of NEMO (-) MEFs was carried out also using Lipofectamine 
2000 mediated transfections, according to the manufacturer’s instructions 
(Invitrogen). All transfections included supplemental empty vector to ensure 
that the total amount of transfected DNA was kept constant in each dish 
culture. 
Transfection of HEK 293T cells in 6-well dishes was carried out using a 
standard Calcium Phosphate procedure. In each transfection protocol, an 
internal control (eF1-lacZ) was included to correct for variations between 
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the samples (Kovalenko, Chable-Bessia et al. 2003). β-galactosidase activity 
was measured using Luminescent β-galactosidase Reporter System 3 from 
Clontech.  
3.7  Retroviral Infections 
 
Gene transfer was achieved by a retrovirus-mediated process. The 
retrovirus pBabe-NEMO, its mutant forms and control pBabe-puro were 
used to infect Mefs NEMO (-) cells. Cell lines expressing NEMO and its 
mutants were selected along with a pBabe-puro control line. The expression 
of NEMO was detected by immunoblot analysis. 
The pBabe-NEMO plasmids and empty pBabe-puro were used to transfect 
LinX packaging cells, using the standard CaPO3 procedure. Conditioned 
media (48-hour culture) collected from the transfected LinX cells were 
filtered through a 0.45-µm pore size syringe filter. The viral supernatants 
were mixed with defined DMEM (1:1). This mixture, supplemented with 
polybrene (8 µg/mL), was added to recipient cells, Mefs Nemo(-/-), that had 
been plated at 5 x 105 cells per 100-mm dish the day before infection. Mefs 
cells were cultured in viral supernatants for 10 hours followed by 12 hours 
in DMEM supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 
100mg/ml streptomycin. After 12h the cells were subjected to selection in 2 
µg/mL puromycin for 14 to 21 days. A pool of puromycin-resistant cells 
was obtained. The selected cells were then maintained in a defined Mefs 
medium. 
 
3.8  Immunoprecipitation and Western blotting 
 
HEK 293T cells transfected were recovered by gentle pipeting in 1 
ml of PBS. They were centrifuged at 6000 rpm for 1min in a microfuge and 
resuspended in 50-100 µl of TNT buffer (200 mM NaCl, 1 % Triton X-100, 
20 mM Tris-HCl, pH 7.5). After incubation on ice for 10 min and 
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centrifugation at 14000 rpm for 10 min, the supernatant was recovered and 
the protein concentration determined. One hundred to 200 µg of proteins (in 
200 µl of TNT) were either directly analyzed, after electrophoresis, by 
Western blotting (see below) or immunoprecipitated. In this latter case, 
extracts were incubated under rotation for 1h at 4°C with the relevant 
antibody. Protein A- or protein G-Sepharose was then added and the 
mixture incubated for 30 more min at 4°C. Sepharose beads were quickly 
centrifuged in a microfuge (30s at 14000 rpm) and washed four times with 
TNF. After the final wash, the beads were resuspended in 30 µl of Buffer A 
(10 mM KCl, 2 mM MgCl2, 0.1 mM EDTA, 1 mM DTT, 10 mM Hepes 
(pH 7,8). For immunoprecipitation of transfected proteins, MEFs cells were 
transiently transfected and 24 h after transfection cells were lysed in Triton 
X-100 lysis buffer (20mM Hepes, pH 7.4, 150 mM NaCl, 10% glycerol, 1% 
Triton X-100, and Complete Protease Inhibitor mixture). After an additional 
10 min on ice, cell extracts were centrifuged for 10 min at 14,000g at 4°C 
and supernatants were incubated for 4 h at 4°C with anti-FLAG antibodies 
bound to agarose beads (M2, Sigma). The immunoprecipitates were washed 
five times with Triton X-100 lysis buffer and subjected to SDS–PAGE. Gels 
were transfered at 100 V for 1h onto Immun-Blot PVDF membranes 
(BioRad) which were blocked in 4% dry milk/PBS for 1h. Incubation with 
the relevant Ab was carried out in 0.4% dry milk/PBS for 1h. The 
membrane was washed three times in 0.05 % Tween/PBS for 10 min and 
incubated with the secondary HPR-linked antibody for 45 min in 0.4 % dry 
milk/PBS. After the final washes, membranes were analyzed using either 
ECL + (Amersham) or SuperSignal West Pico Chemiluminescent Kit 
(Pierce). 
  
 
 
 
 
4. RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 RESULTS 
 
 
 
  
 
29 
 
4.1  NEMO mutations in IP 
 
Between 70 and 80% of IP patients exhibit the same genomic 
rearrangement that deletes the locus encoding NEMO.  
The most frequent mutation in females IP is the exon4_10 deletion (c.399-
?_1260+?del) which occurs between two identical MER67B repeats (Figure 
7). This recurrent deletion (c.399-?_1260+?del) eliminates ~11kb of the 
NEMO gene (also called IKBKG) and it is lethal in males.  
Considering the data that have been published during the last eight years a 
total of 47 different mutations have been described: 27 are frameshift, 11 are 
nonsense, 2 are splice site mutations and one is a nonstop mutation. Among 
the remaining patients only few small mutations (5 missense and 1 in frame 
deletion of one codon) of NEMO have been described. Most of the missense 
mutations found in IP affect residues conserved in vertebrates during 
evolution (Table 3)(Fusco, Pescatore et al. 2008). 
The overall mutation detection rate in IP is 73%. However, extensive 
research is still in progress to identify new genomic rearrangements, which 
may account for the remaining 27% of IP patients without the NEMO 
mutation. The NEMO region in humans is particularly full of repetitive 
sequences and therefore must be considered a rearrangement-prone region 
(Aradhya, Bardaro et al. 2001). A non-functional partial second copy of the 
NEMO gene, deltaNEMO, is located 31.6 Kb distal to exon10 (Figure 7). 
NEMO maps within a 35.5 Kb duplicated fragment (>99% identity) opposite 
to NEMO in orientation. It contains the exons 3-10 and carries the two 
MER67B repeats, which also may recombine (Aradhya, Bardaro et al. 
2001). Although, no evidence of an involvement of the NEMO pseudogene 
in human diseases has so far been reported, the non-pathological exon 4_10 
deletion of deltaNEMO has been found in two families, in unaffected 
parents of females with a clinical diagnosis of IP. As a consequence, to 
formulate a correct molecular diagnosis of IP is important to discriminate 
between mutations occurring in NEMO or in its pseudogene. Indeed, the IP 
locus undergoes recombination producing benign variants that might be ‘‘at 
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risk’’ of generating de novo NEMO deletion during either meiotic or mitotic 
division (Fusco, Paciolla et al. 2009).  
The molecular characterization of missense mutations may provide precious 
info regarding the in vivo function of NEMO in NF-κB signalling. 
The first mutation I decided to analyze is a new mutation, a G to C 
transvertion mutation at nucleotide 967 (numbered from the ATG initiation 
codon), which results in a substitution of Alanine 323 in a Proine mutation 
(A323P) located at the beginning of the leucine zipper (LZ) of NEMO 
protein. Furthermore,  I  analyzed other mutations of NEMO (E57K, DK90, 
D113N and R123W) that have been recently described and are located 
within the first 150 aa of the protein, encompassing the region of IKK 
binding domain (Table 3). 
 
4.2  Molecular characterization of a new missense 
mutation of NEMO causing a severe form of Incontinentia 
Pigmenti 
 
In the Dr. Ursini’s Lab, we sequenced the NEMO gene of a newborn 
girl exhibiting a severe form of IP associated with neurological 
abnormalities (see « Case Report » in the Material and Methods section). A 
heterozygous G to C transvertion mutation at nucleotide 967 (numbered 
from the ATG initiation codon) was found, which resulted in a missense 
mutation (A323P) located at the beginning of the NEMO leucine zipper 
(Figure 8A ). 
X-inactivation skewing in the proband’s peripheral blood cells was above 
90% (Figure 8A), as observed in most IP cases, precluding any study of 
cells directly derived from the patient. In order to evaluate the impact of the 
mutation on NF-κB signaling I took advantage of the recent isolation and 
characterization of several cell lines lacking NEMO to complement them 
transiently with a plasmid expressing A323P NEMO and to analyze their 
response to several stimuli, among them TNF, IL-1, LPS and 
PMA/Ionomycine. Two of these cell lines, 1.3E2 and SVT-2C, are 
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lymphocytes of the murine pre-B and human T-cell lineage, respectively 
(Courtois, Whiteside et al. 1997; Harhaj, Good et al. 2000; Schmidt-
Supprian, Bloch et al. 2000), whereas NEMO (-) MEFs are fibroblasts that 
have been derived from a mouse model of IP (Schmidt-Supprian, Bloch et 
al. 2000) 
In the two cell types in which I carried out the analysis, SVT-2C and NEMO 
(-) MEFs, an abolished activation of an NF-κB reporter gene in response to 
TNF was observed after expressing A323P NEMO (Figure 8B). In addition, 
a strong reduction of activation was detected when NEMO (-) MEFs were 
transfected with A323P NEMO and stimulated with IL-1. Finally, in 1.3E2 
cells, I checked the effect of A323P mutation on NF-κΒ activation induced 
by LPS stimulation. Again, an impaired response was observed. Although 
defective TCR signaling is not observed in IP patients, because of the 
efficient chromosome X-driven elimination of T lymphocytes harboring 
NEMO mutations, I wondered whether this pathway was also affected by 
A323P mutation. Whereas transient complemention of SVT-2C cells with 
wt NEMO followed by PMA/Ionomycin stimulation resulted in potent NF-
Β activation no such activation was seen upon complemention with A323P 
mutation (Figure 8B). From this set of data I could conclude that A323P 
mutation exhibited a strong defect in NF-κΒ signaling affecting several 
distinct signaling pathways. Importantly, this aspect was not caused by 
some major structural alteration of the NEMO molecule since A323P 
mutation did not show any defective interaction with previously identified 
partners such as IKK-2 or RIP, as assessed by performing co-transfection 
experiments and immunoprecipitations in HEK 293T cells (Figure 9A, B). 
All the complementation experiments described above were carried out by 
transiently transfecting cell lines, a method that did not allow to detect 
expression of the molecules produced after transfection. To exclude any 
general impairement in NF-Β activation resulting from instability of the 
NEMO protein I generated stable cell lines expressing either wt or A323P 
NEMO proteins. As shown in Figure 8C, pools of SVT-2C cells expressed 
WT or A323P NEMO at a similar level, demonstrating that the mutated 
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protein was stable. Moreover, normal incorporation of A323P NEMO into 
the IKK complex was confirmed by co-immunoprecipitating a similar 
amount of IKK1 and IKK2 as with wt NEMO (Figure 8C, 9A). From this 
set of data, I concluded that A323P mutation exhibited a specific 
impairment affecting at least two distinct pathways of NF-κB activation, the 
TNF and the IL-1/TLR signaling pathways, that bear relevance to the 
phenotype developed by IP patients. 
  
4.3  Defective NEMO polyubiquitination caused by 
A323P mutation 
 
It has previously shown that co-transfecting plamids expressing 
NEMO and ubiquitin in 293T cells results in NEMO K63-linked 
polyubiquitination and that this kind of modification does not regulate the 
stability of this protein but may, through an unclear mechanism, regulate its 
function. Interestingly, when A323P NEMO ubiquitination was monitored 
using this specific assay a severe reduction in ubiquitination was observed 
(Figure 10A). I therefore invested some efforts in trying to identify which 
pathway may be responsible for this basal ubiquitination process. To a large 
extent, NEMO ubiquitination was diminished upon co-transfection of a 
dominant negative version of TRAF-6, something that was not observed 
using a dominant negative version of TRAF-2 (Figure 10B). This suggested 
that some TRAF-6 dependent pathway may be responsible for NEMO 
ubiquitination. Accordingly, when TRAF-6 was co-expressed with both wt 
NEMO and ubiquitin, a strong increase in NEMO ubiquitination was 
observed. In this assay again, A323P mutation exhibited defective 
ubiquitination (Figure 10C). 
 
4.4  Identification of TRAF-6-dependent NEMO 
ubiquitination sites 
 
The observation that TRAF-6-dependent ubiquitination of NEMO 
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was impaired upon mutation of A323 suggested that this may provide a clue 
to identify the specific lysine residues targeted by TRAF-6.  
To independently confirm that the region of NEMO containing A323P 
mutation indeed provided ubiquitination sites for TRAF6, a deletion 
analysis was also carried out, using either C-ter or N-ter truncations of the 
murine protein. This analysis of TRAF6-mediated ubiquitination confirmed 
the existence of ubiquitination sites between aa 343 and aa 299 (Figure 
12A). 
For practical reasons, all the follow experiments were performed 
using mouse NEMO, after confirming that V316P mutation behaved 
equivalently to human A323P mutation (Figure 11A). As shown on Figure 
11B, two conserved lysines (hK321 and hK326, human coordinates; mK314 
and mK319, mouse coordinates) are located in close proximity to hAla 323 
(mVal 316) and could be affected by the appearance of a Proline nearby. To 
check for this possibility, experiments were carried out as described above, 
using a triple mutation targeting the mK318, mK319, mK314 (K was 
mutated in R, mutant 3R). A defective ubiquitination was found despite 
mutant 3R did not completely abolish TRAF-6-induced NEMO 
ubiquitination, suggesting the existence of additional acceptor sites (Figure 
12B). 
Interestingly, a lysine residue of NEMO modified by the Nod2/RICK 
signaling pathway, which is perturbed in Crohn disease, has been identified 
at hK285 (Abbott, Yang et al. 2007). Moreover, the E3 ligase used by 
Nod2/RICK to ubiquitinate this site has not been defined. I therefore tested 
the possiblity that it may represent an additional target of TRAF-6 since, as 
mentionned above, I observed some residual NEMO ubiquitination taking 
place upstream of aa 299. Accordingly, the residual ubiquitination of 3R 
was almost totally abolished upon mutating mK278 also (construct 4R) 
(Figure 12B). 
Having identified several distinct lysines of NEMO that may represent sites 
for TRAF-6-dependent polyubiquitination I investigated the impact of their 
mutation on NF-κB signaling.  
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I first analyzed 3R or 4R mutants on the activation of NF-κB by IL-1, which 
is a prototypical cytokine using TRAF-6 E3 ligase. Since defective TRAF-6 
mediated ubiquitination of NEMO requires the mutation of several of these 
residues (see above), In both mutants 3R and 4R a 40% of reduction in NF-
κB activation was observed. In the same assay, activation of NF-κB by TNF 
was not significantly affected by mutation 4R, indicating that the newly 
identified sites of ubiquitination were specifically required by a stimulus 
using TRAF6 (Figure 13). 
I next checked whether other signaling pathways known to activate 
NF-κB through TRAF-6 were also dependent upon NEMO ubiquitination. 
Activation of NF-κB by LPS, which relies upon a TLR-dependent signaling 
pathway was more than 60 % impaired when NEMO (-) MEFs were 
complemented with 5R mutant (mutating residue mK392, which has been 
reported involved in the TCR signaling, in construct 4R) (Figure 13). 
I finally analyzed the contribution of NEMO ubiquitination to pathways that 
remain less well characterized but might also require TRAF-6. 
Very recently, a participation of Bcl10/MALT-1 in NF- κB activation by 
LPA, a major component of serum exhibiting mitogenic properties, has been 
reported (Klemm, Zimmermann et al. 2007). Importantly, Bcl10/MALT-1 
complex appears to act through TRAF-6. I therefore analyzed whether 
TRAF-6-dependent NEMO ubiquitination was involved in serum- and LPA-
induced NF- κB activation. The activation of NF-κB was compromised 
when NEMO (-) MEFs were complemented with 5R mutant (Figure 13). 
This indicates that NEMO ubiquitination also plays an essential role in 
serum-induced NF-κB activation.  
 
4.5  E57K: the masked mutant  
 
In order to evaluate the impact of the E57K mutation on NF-κB 
signaling, I transiently complement cell lines lacking NEMO with a plasmid 
expressing E57K NEMO and I analyzed its response to several stimuli, 
among them TNF, IL-1, LPS. Despite repeated attempts, I was unable to 
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detect any reproducible reduction of NF-κB activation in response to IL-1 or 
LPS when NEMO (-) 1.3E2 cells or NEMO (-) MEFs were transiently 
complemented with E57K NEMO (data not shown). This mutation has been 
associated with a mild form of IP so, to further investigate if E57K NEMO 
really affected the IL-1 pathway, I generated stably MEFs NEMO (-) 
expressing WT NEMO or E57K NEMO at physiological levels. This 
allowed me to discover its putative effect on NF-κB signaling. As shown in 
Figure 14A, pools of MEFs expressing identical level wt or E57K NEMO 
were obtained after retroviral infection (lower panel). The protein 
expression level was similar to the endogenous NEMO in wt MEFs, 
confirming the stability of E57K NEMO protein.  
I next investigated the effect of E57K NEMO on NF-κB activation. 
Upon treatment with IL-1, NF-κB activation in E57K-expressing cells 
appeared reduced (approximately 45%) compared to wt NEMO-expressing 
cells (Figure 14A). Moreover, activation of NF-κB following TRAF6 
overexpression was also reduced (Figure 14A), indicating a specific defect 
involving this E3 ubiquitin ligase. Finally, mutation E57K did not impair 
NF-κB activation when TNF was used as a stimulus. This suggested that 
E57K mutation found in IP was specifically associated with impaired NF-
κB stimulation in response to TRAF-6 mediated activation.  
Significantly, E57K NEMO mutant did not affect integration of NEMO into 
IKK (Figure 14B). Moreover, to confirm a correct IKK activation I 
stimulated stably cells expressing NEMO or E57K NEMO mutant with 
TNF-alfa. In both cases a normal IκB-alfa degradation was observed (Figure 
14B lower panel). 
 
4.6  E57K is defective in TRAF6 binding 
 
Because TRAF-6 has been proposed to act as an E3 ligase for 
NEMO, I wondered at which step E57K mutation perturbed the IL-1 
signaling. As shown in Figure 15, a specific interaction between TRAF-6 
and wt NEMO was detected after co-transfecting the two molecules in HEK 
 RESULTS 
 
 
 
  
 
36 
 
293T cells. The presence of NEMO was observed in the Flag-TRAF6 
immunoprecipitated extracts. In contrast, by co-transfecting NEMO E57K 
mutant, a decreased amount of protein was pulled down by TRAF6, 
indicating that the recognition between NEMO and TRAF-6 was defective, 
most likely causing the subsequent defect in IL-1 pathway (Figure 15A). 
There are a subclass of IP-causing mutation comprises 2 missense mutations 
and a single aa deletion of NEMO that are located within the first 150 aa of 
the protein (DK90, D113N and R123W). I decided to investigate their 
interaction with TRAF6 and I found that they associated equally with 
TRAF6 (Figure 15B and data not shown).  Importantly, the DK90 mutant, 
showing a strong defect in IKK kinases binding (see below), did not have 
any defect in TRAF6 interaction. Likewise, as previously discussed, E57K 
did not affect binding to both IKK related kinases, indicating that separate 
neighboring sequences are required for binding of TRAF6 and IKK to 
NEMO. 
In parallel, to confirm that the region of NEMO containing E57K 
mutation provided binding site for TRAF6, a deletion analysis was also 
carried out using small internal deletions  located at the N-terminus of the 
NEMO protein (see Marienfeld, Palkowitsch et al. 2006 for details). 
Removing aa 47 to 56 (del5) reduced to some extent TRAF6 binding 
whereas removing aa 57 to 69 (del6) was very deleterious. In contrast, 
removing aa 70 to 79 (del7) appeared without any effect (Figure 15C). 
Importantly, also in this case, the interaction of del6 with IKK2 was 
unaffected (Marienfeld, Palkowitsch et al. 2006). Collectively, these results 
strongly suggest that the defect in TRAF6 interaction was not caused by the 
absence of a small helical domain participating in IKK recognition at the N-
terminus of NEMO. 
 
4.7  Mapping the TRAF6 binding site of NEMO 
 
Several truncated forms of TRAF6 were examined for their ability to 
interact with NEMO (Figure 16A). Like other TRAFs, TRAF6 has a 
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conserved C-terminus TRAF-C domain, a TRAF-N domain and an N-
terminus ring finger (Cao, Xiong et al. 1996).  
Removing the first 297 aa of TRAF6, which contain both the ring finger and 
the five zinc fingers did not affect binding of TRAF6 to NEMO (Fig. 16B, 
lower panel). In contrast, the interaction was lost deleting C-terminus 
portion of the TRAFN domain such as in Del330 TRAF6 (Figure 16B, 
upper panel). Conversely, deleting the TRAFC domain of TRAF6 did not 
affect binding of TRAF6 to NEMO (Figure 16B, upper panel) but 
eliminating N-terminus of the TRAFN domain, such as in DC308 TRAF6, 
impaired NEMO binding. This suggested that TRAFN domain of TRAF6, 
which was predicted to have a structure of a coiled coil (CC), might be 
responsible for TRAF6 interaction with the N-terminus of NEMO. To 
confirm this hypothesis an internal deletion of TRAF6 only lacking residues 
301 to 358 (DCC-TRAF6) was prepared. It exhibited a strong defect in 
NEMO binding (Figure 16B, lower panel). While all TRAF6 residues 
present at its interface with NEMO are conserved among species, most are 
not conserved in TRAF2 that is known to mediate NF-κB activation in TNF 
pathway.  In fact, the full-length of TRAF2 did not interacts with NEMO in 
the same assay using 293T cells. Taken together, these results clearly 
indicated that the CC domain of TRAF6 played a key role in mediating 
direct interaction with NEMO.  
 
4.8  The Lysine 90: the critical residue for IKK complex 
formation 
 
I decided to further investigate an in frame delition of a codon (266-
269delAGA) leading to a microdeletion of a K-90 (DK90) falling in the 
CC1 domain of NEMO protein. The DK90 mutation has been found in a 
patient suffering from a severe form of IP in which also nervous system 
(brain atrophy, microcephaly, mental retardation, epilepsy and spastic 
paralysis were observed) and eyes are affected (strabismus and retinal 
haemorrhage were shown). The mutation was published in 2004 (Fusco, 
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Bardaro et al. 2004) but its molecular defect was not completely resolved.  
To add informations regarding the functional relevance of K90, I 
complemented MEFs NEMO (-) cells via retroviral infection. I assessed the 
NF-κB activation after TNF and IL-1 stimulation. As shown in Figure 17A, 
DK90 exhibited a strong impairment affecting both the TNF and the IL-1 
signaling pathways. Importantly, a correct expression of DK90 NEMO 
mutant protein was confirmed by western blot analysis (figure 17A).  
Later on, since the IKK-binding region of NEMO has recently been 
confined to residues 47-120 (Marienfeld, Palkowitsch et al. 2006), I 
investigated the ability of DK90 to associate with IKKs in HEK293T cells.  
Cells were transiently co-transfected with DK90 or NEMO 
expression vector in combinations with either FLAG–IKK2 or HA-IKK1 
plasmids. Cell extracts were immunoprecipitated with an anti-FLAG 
antibody or anti-NEMO and then analyzed by immunoblotting assay with an 
anti-NEMO or anti-HA respectively (Fig. 17B). 
I found that a deletion of a K90 completely abolish the NEMO 
interaction with IKK1 while strongly reduced its interaction with IKK2 
demonstrating a critical role of the K90 residue in NEMO/IKK complex 
formation.  
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Incontinentia Pigmenti (IP) is the first genetic disease associated to 
NF-κB alteration. It provides the best insight into the physiological role of 
the regulatory subunit NEMO in the IKK complex activation. To this 
respect, the characterization of IP-related NEMO mutants represents an 
exclusive opportunity to elucidate the molecular mechanism of IKK 
regulation. In this study, I reported on the molecular characterization of 
three IP-related NEMO mutation, two are missense mutations, A323P and 
E57K, and one is an in frame deletion causing the delition of Lisine 90 
(DK90).  
A323P is a newly described mutation found in a patient suffering for 
a severe form of IP. As expected, this substitution caused a severe defect in 
NF-κB activation involving several distinct pathways. I found that A323P 
shown an impaired TRAF6-dependent NEMO ubiquitination, explaining the 
defects associated to IL-1 and LPS signaling. In addition, by site directed 
mutagenesis and a deletion analysis of NEMO, I have identified three new 
lysine residues, located around A323, which are targeted by TRAF6. The 
critical TRAF-6-dependent ubiquitinated sites on NEMO are required for 
NF-κB activation and appear to integrate signaling pathways that are used 
by a variety of stimuli all using TRAF6 as E3 ligase. It remains uncertain 
how their modification by ubiquitination influence the IKK activation 
process, in particular if they provide a primary tag for building up 
interactions between components regulating IKK activity or represent the 
final step triggering its catalytic activation.. 
Regarding the A323P defect in TNF-mediated activation, it is 
noteworthy to mention that during my characterization of this mutant, three 
unrelated groups showed the existence of the “sensor” pathway. Upon TNF 
stimulation, NEMO, through NUB domain, appears to act as a sensor to 
associate to the ubiquitinated RIP leading to the IKK activation. Point 
mutations within the NUB domain have been reported to impair recognition 
of ubiquitinated RIP by NEMO. Since A323P is located in close proximity 
of NUB, it is likely that impaired NF-κB activation in response to TNF is 
caused by a defective recruitment of IKK to TNF-R1 (Ea, Deng et al. 2006; 
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Li, Kobayashi et al. 2006; Wu, Conze et al. 2006).  
Dissecting the molecular defects associated to E57K missense 
mutation I have discovered a new protein/protein interface that is required 
for NEMO/TRAF6 interaction.  
NEMO E57K mutation was associated to a specific defect in IL-1-mediated 
NF-κB activation, resulting from a reduced interaction between E57K 
NEMO and TRAF6. The sequence involved in this interaction, located at 
the N-terminus of NEMO, has been shown also to bind IKK1 and 2. Ruche 
and colleagues have recently demonstrated that the N-terminus part of 
NEMO (44-111) is formed of distinct alfa-helical subdomains, which not 
only provide interfaces for heterotypic interaction with IKK1/IKK2 but also 
allow dimerization of NEMO. Moreover, they have solved the crystal 
structure of the NEMO/IKK interaction and several critical residues of 
NEMO, participating either in recognition by IKKs or in NEMO 
dimerization, have been identified (Rushe, Silvian et al. 2008). In particular, 
the E57 residue appears to participate in NEMO N-ter dimerization. Thus, I 
hypothesized that a single modification of this binding interface, like the 
change of charge resulting from E57K mutation, may specifically perturb 
the binding of NEMO to TRAF6.  
On the TRAF6 side, a new putative function of the TRAF6 CC in NF-κB 
activation has emerged. Until now, the role of this domain was quite unclear 
in contrast to the well-known functions of the ring finger and TRAF-C 
domains. TRAF6 has been shown to play key roles in NF-κB-dependent 
signaling pathways controlling most cellular processes. It therefore 
represents an attractive target for inhibiting NF-κB activation when its 
activation is dysregulated, such as in inflammation, cancer or autoimmunity. 
The last mutation I analysed is DK90, an in frame deletion of a 
codon resulting in a Lisine deletion at position 90. In this case, detailed 
analysis of NF-κB activity in response to TNF, IL-1 and LPS has shown a 
strong defect in all these signaling pathways. I have found that mutant 
protein completely lost its ability to interact with IKK1 while it retained 
some capacity to bind IKK2. This difference probably is due to the higher 
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affinity of IKK2 for NEMO compared with IKK1. Why NEMO has 
different affinities for IKK1 and IKK2 is still unknown but the answer to 
this question may provide a clue in understanding the distinct functions of 
the IKKs. 
In summary, this work provides new insights into the role of NEMO 
in vivo and a better understanding of IP at the cellular and molecular levels.  
Importantly, dissecting specific molecular interactions within the NEMO-
mediated activation could suggest new targets for the development of 
potentially effective therapeutic strategies, not only for this specific 
pathology but also for more common pathologies resulting from NF-κB 
dysfunction.  
However, the main question regarding how these series of molecular 
defects, affecting different signaling pathways, impact on the high variable 
phenotype displayed by the IP patients remains still unclear. In particular, it 
is difficult to understand why some mutations generated severe CNS 
abnormalities. Even if random variations in X-inactivation skewing have 
been shown to cause extended phenotype heterogeneity in patients carrying 
the same NEMO rearrangement, it is possible that a discrete pathway 
participating in CNS development/functioning may be specifically affected 
by A323P or DK90 mutation. Analyzing NEMO-IP mutation in an in vivo 
system, such as knock-in mice, may be useful to verify this hypothesis. 
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Figure 1
Members of NF-κB and IκB protein families
The domains that typify each protein family are indicated, and alternative 
nomenclatures are provided in brackets. The precursor proteins p100 and p105 
function as both inhibitor of nuclear factor-B (NF-κB) proteins and, when
processed by the proteasome, NF-κB family members. ANK, ankyrin-repeat; 
BCL-3, B-cell lymphoma 3; CC, coiled-coil; DD, death domain; GRR, glycine-
rich region; HLH, helix-loop-helix;
Hayden and Ghosh 2008
Figure 2
NF-κB Signaling Pathways
Following receptor ligation and recruitment of receptor proximal adaptor proteins, 
signaling to IKK proceeds through TRAF/RIP complexes, generally in conjunction with
TAK1, leading to canonical NF-κB signaling, or through TRAFs and NIK leading to
the noncanonical NF-κB pathway. IKK activation results in IκB phosphorylation and 
degradation in the canonical pathway or p100 processing to p52 in the noncanonical
pathway. Phosphorylated NF-κB dimers bind to κB DNA elements and induce 
transcription of target genes.
Hayden and Ghosh, 2008
Figure 3
Structure of the IKK subunits.
Schematic rapresentation of the principal structural motifs of IKK-1, IKK-2 and NEMO. 
Numbering is from the human proteins. Abbreviations: LZ, leucin zipper; HLH, Helic-loop-
helic domain; NBD, NEMO-binding domain;  CC1 and CC2, coiled coil regions 1 and 2; ZF, 
zinch finger; NUB, NEMO ubiquitin binding domain. 
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The NEMO interactome.
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Figure 4
The ubiquitin pathway. A) 
Schematic representation of the 
ubiquitination process. A 
hierarchical set of three types of 
enzyme is required for substrate
ubiquitination: ubiquitin-
activating (E1), ubiquitin-
conjugating (E2) and ubiquitin-
protein ligase (E3) enzymes. The 
two major classes of E3 ligases
are depicted. B) Schematic
representation of the different Ub
modifications with their
functional roles. The question
mark indicates that the functions
of branched chains are largely
unknown.
Woelk, T. et al. 2007
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Table 2
Representative proteins involved in ubiquitin-mediated regulation of IKK
Skaug, Jiang et al. 2009
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Figure 5
Role of ubiquitin and IKK complex  in coordinating NF-κB activation.
The major molecules involved in IL-1, TNF and TLR4 signaling pathways and 
participating in NF-κB regulation are presented. 
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Figure 6
Molecular and cellular events associated with IP dermatosis.
(A) Immunohistochemistry analysis of IKK-2 skin K.O. mice. IL-1β and TNF-α expression
is shown at post-natal days 3 (P3), 7 (P7) and 8 (P8). The dotted line indicates the 
epidermis/dermis boundary. Ct: wild-type mouse, mt: IKK-2 skin K.O. mouse. (B) A putative 
model of IP dermatosis. See text for more details. KC: keratinocyte; Fibro: fibroblast; Cap.: 
capillary vessel; MΦ; macrophage; TL: T lymphocyte; Neutro: neutrophil granulocyte.
Sebban and Courtois 2006
Fusco, Pescatore et al. 2008
Table 3
NEMO (also called IKBKG) mutations accounting for IP and EDA-ID.
Figure 7
Schematic representation of the genomic structure of the IP locus.
A) The chromosomal region between 149876356bp and 154515206bp contains the G6PD gene 
(GenBank NM_000402; MIM# 305900), IKBKG gene, CTAG1-B gene (GenBank
NM_001327.2; MIM# 300156),CTAG1-A gene (GenBank NM_139250.1; MIM# 300657), 
IKBKGP pseudogene, and CTAG2 gene. The Inverted Repeats are reported. Nucleotide positions 
are shown according to the UCSC Human Genome Release 2006. Proximal and distal MER67Bs 
are reported in each Inverted Repeat.
B) P4, P5, P6, P7, P8, and P9 amplicons used as real-time PCR probes to study copy number 
elements. P4 and P9 are located in a single copy, P4(1) and P9(1), whereas P5, P6, P7, and P8 are 
located in double sites, P5(2), P6(2), P7(2), P8(2). The most common IP deletion (11.7 kb, 
IKBKGdel) in the gene and the deletion in the pseudogene (11.7 kb, IKBKGPdel) are indicated.
Fusco, Paciolla et al. 2009
A)
Figure 8.
Identification of a missense mutation of NEMO causing a severe form of IP. 
A) Sequence analysis and skewed X-inactivation resulting from G967C mutation. The X-
inactivation status of the proband (II:1) and her mother (I:2) is indicated in percentage. 
B) Phenotype of A323P mutation. Defective response of A323P NEMO mutant to TNF, IL-1, 
LPS and PMA/ionomycin. Luciferase assays, using IgκB -Luc as a reporter plasmid, were carried
out after complementing NEMO (–) cells (SVT-2C, 1.3E2 and MEFs Nemo -/-) with an
expression vector encoding either wt or A323P NEMO. 
C) Stability of A323P mutant. cells extracts derived from Jurkat or SVT-2C stably expressing
NEMO, A323P NEMO or empty vector were analyzed by immunoblotting, using an anti-NEMO
(left panel). The same extracts as in were immunoprecipitated with anti-NEMO and analyzed
with an anti-IKK-1 (right panel). 
B)
C)
Figure 9
A323P NEMO retained the ability to interact  with IKK2 and RIP.
A) HEK 293T cells transiently transfected with Flag-NEMO or Flag-A323P NEMO in combination 
with Flag-IKK2. The extracts were subjected to anti-NEMO immunoprecipitation. The 
coimmunoprecipitated IKK2 was analysed by immunoblotting using an anti-Flag. 
B) Interaction between A323P NEMO and RIP  was analyzed as in A). .
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Figure 10
Defective ubiquitination of A323P mutant.
A) Impaired basal ubiquitination of A323P NEMO. HEK 293T cells were transfected with wt 
NEMO or A323P NEMO alone or with HA-Ub. Cell extracts were analyzed, after western 
blotting, with anti-hNEMO (left panel) or immunoprecipitated with an anti-NEMO and then 
analyzed, after western blotting, with anti-HA. Retarded ubiquitinated forms of NEMO are 
indicated by Ub-NEMO. B) Basal ubiquitination of NEMO is TRAF6-dependent. HEK 293T 
cells were co-transfected with wt NEMO and HA-Ub, without or with a dominant negative 
version of TRAF6 or TRAF2. Cell extracts were prepared and analyzed, after western blotting, 
with NEMO, anti-HA or anti-TRAF6.
C) Impaired TRAF6-dependent 
NEMO ubiquitination caused 
by A323P mutation. HEK 
293T cells were transfected
with wt NEMO (lanes 1–3) or 
A323P NEMO (lanes 4–6). In 
lanes 2 and 5, NEMO proteins 
were co-transfected with HA-
Ub alone, whereas in lanes 3 
and 6 TRAF6 was also 
included.
Figure 11 
Identification of TRAF6-dependent NEMO ubiquitination sites. 
A) Impaired TRAF6-dependent NEMO ubiquitination in murin V316P mutant. B) Defective 
response of murin V316P (corresponding to A323P NEMO) mutant to TNF, IL-1 and LPS. 
Luciferase assays, using IgκB -Luc as a reporter plasmid, were carried out after complementing 
NEMO (–) cells. C) Conserved lysine residues located in close proximity of A323. NEMO 
sequences from various species are aligned to indicate the existence of two conserved lysines
(asterisks). 
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Figure 12
Identification of TRAF6-dependent NEMO ubiquitination sites. 
A) Identification of NEMO ubiquitination sites using C-tel (upper panel) an N-ter (lower panel) 
truncations of NEMO. Various wt and mutated versions of HA-NEMO were co-transfected with 
HA-Ub alone or with Flag-TRAF6. Cells extracts were analyzed, after western blotting, with anti-
NEMO.
B) Mutagenesis analysis of NEMO ubiquitination sites. The analysis was carried out as described in  
A) but co-transfecting with  Flag-TRAF6 and either with (upper panel) ot without HA-Ub (lower 
panel). 
A)
B)
Figure 13
Functional analysis of NEMO ubiquitination sites. 
A) Participation of NEMO ubiquitination in TNF and IL-1 signaling. The analysis was carried out 
as previously, using complementation of NEMO (–) MEFs with the indicated NEMO mutants. 
Cells stimulated for 4 h with the indicated stimuli. In B) LPS stimulation was shown.
C) Participation of NEMO ubiquitination in NF-κB activation by serum and LPA. The analysis 
was carried out as in (A). 
C)
A) B)
Figure 14
The E57 of  NEMO is required for IL-1 mediated NF-κB activation.
A) Expression of MEFs NEMO (-) cells stably complemented with WT NEMO or E57K NEMO 
(lower panel) and luciferase activity of NF-κB (upper panel) in response to TNF-alfa, IL-1 (4h of 
treatment) and TRAF6 overexpression. Error bars represent variation ranges of duplicate 
experiments. B) MEFs cells stably complemented with NEMO or E57K NEMO were transfected
with Flag-IKK2 (upper panel) and the extracts were subjected to anti-flag M2 agarose
immunoprecipitation. The coimmunoprecipitated NEMO were analysed by immunoblotting.  The 
cells, as indicated in the lower panel, were stimulated with TNF-alfa for the indicated time, and 
then the amount of IkBalfa was determined by immunoblotting.  pBabe (or pb) represents the 
empty vector   
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Figure 15
The N-ter domain of  NEMO, including E57 residue, is required for the interaction with 
TRAF6.
A) HEK 293T cells transiently transfected with NEMO or E57K NEMO in combination with 
FlagTRAF6. The extracts were subjected to anti-flag M2 agarose immunoprecipitation. The 
coimmunoprecipitated NEMO was analysed by immunoblotting. B) Interaction between DK90 
NEMO and TRAF6  was analyzed as in A). 
C) Various N-ternunus delitions of NEMO were co-transfected with Flag-TRAF6. Cells extracts 
were innunoprecipitated using an anti NEMO and  analyzed, after western blotting, with anti-Flag.
Figure 16
The CC of TRAF6 is required for the  
interaction with NEMO.
A) Schematic diagrams of TRAF6 and its 
deletion mutants. The RING, zinch
fimger, ZF, coiled coil (CC) and TRAFC 
domains are shown
B) HEK 293T cells transiently 
transfected with NEMO in combination 
with Flag-TRAF6 deletion mutants. The 
extracts were subjected to anti-flag M2 
agarose (upper panel) or anti-NEMO 
(lower panel) immunoprecipitation. 
The immunoprecipitated NEMO or Flag-
TRAF6 were analysed by 
immunoblotting.  
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Figure 17
The K90 of  NEMO is required for IL-1, TNF and TRAF6-mediated NF-κB activation.
A) MEFs NEMO (-) cells stably complemented with NEMO or DK90 NEMO luciferase activity of 
NF-κB in response to TNF-alfa, IL-1 (4h of treatment) and TRAF6 overexpression. Error bars 
represent variation ranges of duplicate experiments. The extracts were subjected to immunoblotting.
B) HEK 293T cells transiently transfected with NEMO or DK90 NEMO in combination with HA-
IKK1 (upper panel) and Flag-IKK2 (lower panel). The extracts were subjected to anti-flag M2 
agarose or anti-NEMO immunoprecipitation. The immunoprecipitated NEMO or HA-IKK1 were 
analysed by immunoblotting.  Pc represents the empty vector (pcDNA3).
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